Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Tufman

Showing results (71-80 of 147) with videos related to

Pageof 15
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|November 17, 2023
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysisKerstin Hofstetter, Julian Taugner, Lukas Käsmann, et al.
Anticancer Research|September 15, 2019
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal TreatmentLukas Käsmann, Julian Taugner, Chukwuka Eze, et al.
Translational Lung Cancer Research|November 19, 2019
Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapyJulian Taugner, Lukas Käsmann, Chukwuka Eze, et al.
Journal of Cancer Research and Clinical Oncology|August 1, 2022
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysisBenedikt Flörsch, Julian Taugner, Lukas Käsmann, et al.
Oncology Research and Treatment|April 9, 2020
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver AlterationsDiego Kauffmann-Guerrero, Amanda Tufman, Kathrin Kahnert, et al.
Frontiers in Immunology|July 14, 2022
Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLCLaura Sellmer, Julia Kovács, Julia Walter, et al.
Oncology Research and Treatment|March 25, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Targeted TherapiesFabian Acker, Jingting Luan, Puyan Soltani Germy, et al.
Oncology Research and Treatment|April 4, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell EngagersMarcel Kemper, Puyan Soltani Germy, Fabian Acker, et al.
Cancers|December 11, 2025
Distinct Clinical and Biological Features of Diffusely Metastatic Versus Bulky Localized Lung Cancer: Real-World Outcomes from a University Cancer Center in GermanyBlerina Resuli, Julia Walter, Diego Kauffmann-Guerrero, et al.
Endocrine|February 2, 2018
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apneaDaniel A Heinrich, Claudia Reinholz, Maximilian Bauer, et al.
Pageof 15

Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|November 17, 2023
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysisKerstin Hofstetter, Julian Taugner, Lukas Käsmann, et al.
Anticancer Research|September 15, 2019
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal TreatmentLukas Käsmann, Julian Taugner, Chukwuka Eze, et al.
Translational Lung Cancer Research|November 19, 2019
Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapyJulian Taugner, Lukas Käsmann, Chukwuka Eze, et al.
Journal of Cancer Research and Clinical Oncology|August 1, 2022
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysisBenedikt Flörsch, Julian Taugner, Lukas Käsmann, et al.
Oncology Research and Treatment|April 9, 2020
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver AlterationsDiego Kauffmann-Guerrero, Amanda Tufman, Kathrin Kahnert, et al.
Frontiers in Immunology|July 14, 2022
Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLCLaura Sellmer, Julia Kovács, Julia Walter, et al.
Oncology Research and Treatment|March 25, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Targeted TherapiesFabian Acker, Jingting Luan, Puyan Soltani Germy, et al.
Oncology Research and Treatment|April 4, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell EngagersMarcel Kemper, Puyan Soltani Germy, Fabian Acker, et al.
Cancers|December 11, 2025
Distinct Clinical and Biological Features of Diffusely Metastatic Versus Bulky Localized Lung Cancer: Real-World Outcomes from a University Cancer Center in GermanyBlerina Resuli, Julia Walter, Diego Kauffmann-Guerrero, et al.
Endocrine|February 2, 2018
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apneaDaniel A Heinrich, Claudia Reinholz, Maximilian Bauer, et al.
Pageof 15